Combined with their existing high-field multidimensional NMR technology, the new Olaris QqQ panel enables global, quantitative reproducible measurements of hundreds of metabolites for clinical and biopharmaceutical research.
FRAMINGHAM, Mass., June 5, 2023 /PRNewswire-PRWeb/ — Olaris, Inc., a precision medicine company leveraging metabolomics and machine learning to discover and develop its myOLARIS™ diagnostics products, is pleased to announce that the company’s research on developing a triple-quadrupole (QqQ) mass spectrometry (MS) platform for clinical metabolomics applications has been selected for a poster presentation on June 5th at the upcoming American Society for Mass Spectrometry (ASMS) 2023 Annual Meeting, to be held June 4th-8th in Houston, TX.
“The new QqQ technology will expand our ability to detect clinically impactful changes in metabolites. Coupled with our CEREBRO machine learning platform, Olaris offers an end-to-end solution for biomarker discovery for internal discovery efforts and as an offering to our strategic partners.” said Dr. Elizabeth O’Day, CEO and Founder of Olaris.
Metabolites, small molecules involved in generating energy and maintaining our bodies, are altered with disease status and treatment response and therefore provide the most useful biomarkers for real-time measurements of clinical outcomes in biomedical and pharmaceutical research. Yet due to challenges with analytical measurements and reproducibility concerns, metabolomics has yet to reach its full potential in diagnostic and drug development. With its pioneering nuclear magnetic resonance (NMR) and now MS capabilities, Olaris is set to change this. The new QqQ MS platform is highly standardized, providing fidelity across batches, requires minimal sample volume, and enables accurate and reproducible measurements for +370 metabolites that span across biological pathways.
“Until now, in clinical metabolomics there was a tradeoff between measuring many hundreds of metabolites with limited accuracy and reproducibility or measuring highly accurate concentrations of only a limited set of metabolites. Olaris’ new MS method, combined with our existing NMR platform, eliminates this tradeoff, providing broad coverage of the metabolome, accuracy, and reproducibility at scale,” said Dr. Jurre Kamphorst, VP of MS Technology and Biomarkers at Olaris, who will present the research poster at ASMS.
For more information on the ASMS meeting or to view the Olaris presentation during the conference, visit http://www.asms.org. The presentation will be made available on Olaris’ website at http://www.myolaris.com/news following the conference.
Olaris is on a mission to revolutionize how diseases are diagnosed and treated. By leveraging our CEREBRO platform (Comprehensive Early Responsive Evaluation of Biomarkers Related to Outcomes), which combines metabolomics and machine learning, we harness the power of the body’s own communication system to discover and develop our pipeline of myOLARIS™ precision diagnostics.
To learn more, visit https://www.myolaris.com/
Keri Sheehan, Olaris, 1 6178723813, [email protected]